ArticleFrontiers in human neuroscience2026
Deep brain stimulation clinical trials: a framework to accelerate recruitment, retention, and technology translation.
Article in Frontiers in human neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Clinical trials involving deep brain stimulation (DBS) are challenging to implement due to invasiveness and complexity of the therapy, substantial barriers to participant recruitment and retention, and difficulties translating emerging technologies into routine clinical practice. The 2023 Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Workshop on Patient Recruitment in DBS Clinical Trials convened experts in clinical care, research, engineering, neuroethics, and device regulation to discuss barriers and facilitators related to recruitment, retention, and clinical translation of DBS technologies. The critical barriers to recruitment and retention included limited awareness and misinformation surrounding DBS, participant burden, and complex or inflexible trial protocols. Workshop participants identified several strategies to overcome these barriers, including improving public education, employing patient-centered study designs, engaging participants as equal stakeholders in the research, fostering partnerships with community organizations and referring clinicians, and reducing logistical, financial, and technological burdens associated with participation. Participants also identified barriers to broader clinical translation, including opaque pathways to regulatory approval and insurance coverage, access to specialized care, and adoption of new technologies. To overcome these challenges, participants emphasized the need for objective milestones, outcomes, and biomarkers, pragmatic study design, shared frameworks to support reimbursement efforts, and continued investment in multidisciplinary education and workforce development. Collectively, the workshop attendees concluded accelerating DBS innovation will require interdisciplinary collaborations among patients and patient advocates, community organizations, engineers, industry partners, researchers, clinicians, and regulatory stakeholders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.